That would be brilliant , the one thing DXB did was keep the SOI low (shares on issue) and that amplifies the SP Value.

I noted that PXS travelled above a dollar between 2005 and 2013 , Hitting a high $4.14 on 2nd November 2007,, can I ask you as a LTH "what caused the drop"? thanks NZT

It looks like PXS did a phenomenal amount of ground work , preclinical trials and the Phase I on the catalogue of Treatments that are now completing the Phase II Trials..

This popped up on the News radar last week from Parkinson UK website https://www.parkinsons.org.uk/news/pioneering-uk-trial-underway-tackle-early-causes-parkinsons
Now considering there are entire listed companies in the Parkinson space with a Higher MC than SNT with a single Treatment Offering , it would seem SNT with Multiple Drug Candidates working through the Phase II Trail Process is chronically undervalued and is suffering from poor Market Awareness.

Pioneering UK trial underway to tackle early causes of Parkinson’s

7 May 2025

A clinical trial for people with a sleep disorder who are at higher risk of developing Parkinson’s has begun in Oxfordshire.

The Parkinson’s UK funded trial is part of a global effort with Australian drug discovery company, Syntara. It aims to uncover whether a potential treatment can reduce inflammation in the brain, to hopefully protect brain cells from dying over time.

The trial is investigating a drug, called SNT-4728, in people with isolated rapid eye movement sleep behaviour disorder (iRBD). iRBD is a diagnosed condition where people act out their dreams, sometimes multiple times a night. Research has shown that people with the condition have a higher risk of developing Parkinson’s.

With research sites in Australia already active, the UK now joins the partnership to better understand the earliest causes and signs of Parkinson’s, trialling a drug that aims to slow down or stop the condition from developing.

Francis, 1 of 40 participants, who is living with iRBD, kicked off the start of the UK part of the trial earlier this week. He received the first dose of either the active medication or the placebo (a dummy medication that looks like the real thing) and will continue to take this over the next 12 weeks.

What’s next?

If this small trial is successful it could pave the way for a larger study to continue to understand the potential of this drug for people with Parkinson’s.

Dr Arthur Roach, Director of the Parkinson’s Virtual Biotech at Parkinson’s UK, said:
"This trial represents a beacon of hope for the Parkinson’s community. By focusing on those at higher risk of developing the condition, we are not only advancing our understanding of Parkinson’s but also exploring a possible treatment that could alter the course of the condition, or even delay its appearance".

Dr Jana Baskar, Chief Medical Officer at Syntara, said: “My mother has Parkinson’s so I have a personal motivation to help deliver this clinical trial and progress this area of research towards a treatment that could slow or stop the onset of the condition. This would be life changing for so many people".